Clinical trial · Interventional
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma
NCT02828124CI-TRIAL-00036812terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business objectives have changed
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986183 | Biological | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Dose Escalation Monotherapy
- interventionNames
- Biological: BMS-986183
- type
- EXPERIMENTAL
- label
- Dose Expansion Monotherapy
- interventionNames
- Biological: BMS-986183
- type
- EXPERIMENTAL
- label
- Dose Escalation Combination Therapy
- interventionNames
- Biological: BMS-986183
- Biological: Nivolumab
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must have advanced liver cancer that cannot be treated with surgery or other local methods * Liver cancer is confirmed by a microscopic examination of tissue * Liver disease is classified as 'A' by a standard method called Child-Pugh score * Daily living abilities are classified as '0 or 1' by a standard method from the Eastern Cooperative Oncology Group (ECOG) * Women must use contraception Exclusion Criteria: * Prior liver transplant * Increase in blood pressure in some of the veins entering the liver * Cancer that has spread to the brain or the layers of tissue that cover the brain or spinal cord * Infection with both hepatitis B and C, both hepatitis D and B, infection with HIV, or other infections * Disease of the heart or blood vessels around the heart * Active cancers within the last 2 years * No more than 2 prior systemic treatments or other investigational agents except PD-1/PD-L1 or Ipilimumab (Part 2) * Currently on anti-platelet or anti-coagulation therapy * Radiotherapy within 4 weeks of treatment * Any major allergies Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.